Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Betterlife Pharma Inc (OP: BETRF )

0.0649 +0.0053 (+8.89%)
Streaming Delayed Price Updated: 3:51 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,525
Open 0.0649
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0596
Today's Range 0.0649 - 0.0649
52wk Range 0.0500 - 0.1942
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
From BetterLife Pharma Inc.
Via Globe NewsWire
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga

Performance

YTD
-48.90%
-48.90%
1 Month
-30.66%
-30.66%
3 Month
-44.91%
-44.91%
6 Month
-48.66%
-48.66%
1 Year
-51.96%
-51.96%

More News

Read More
Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic
Via Benzinga
Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
From BetterLife Pharma Inc.
Via Globe NewsWire
BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs
Via Benzinga
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
From BetterLife Pharma Inc.
Via Globe NewsWire
BetterLife Announces Closing of Private Placement
From BetterLife Pharma Inc.
Via Globe NewsWire
Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
Via Benzinga
Study Reveals BetterLife's LSD Analogue Boosts Structural Neuroplasticity Without Hallucinogenic Side Effects
Via Benzinga
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
From BetterLife Pharma Inc.
Via Globe NewsWire
BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs
Via Benzinga
EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So!
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Via Benzinga
What Do You Really Know About Psychedelics And Psychedelics Stocks?
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.